Drug target identification, validation, characterisation and exploitation for treatment of Acanthamoeba (species) infections.
New more efficacious antimicrobials as required for the treatment of Acanthamoeba infections as those currently available require arduous treatment regimes, are not always effective and are poorly active against the cystic stages. Herein, we review potential drug targets including tubulin, alternative oxidase, amino acid biosynthesis and myosin. In addition, we review the literature for current missing tools and resources for the identification, validation and development of new antimicrobials for this organism. Additional targets should come to light through a concerted genome sequencing effort.
Roberts
Craig W
CW
Strathclyde Institute for Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, UK.
Henriquez
Fiona L
FL
D000048:Acanthamoeba / Q000187:drug effects* / Q000235:genetics; D000562:Amebiasis / Q000188:drug therapy*; D000818:Animals; D000981:Antiprotozoal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002482:Cellulose / Q000037:antagonists & inhibitors; D003598:Cytoskeletal Proteins / Q000037:antagonists & inhibitors; D004195:Disease Models, Animal; D006801:Humans; D024101:Mitochondrial Proteins; D009955:Ornithine Decarboxylase / Q000187:drug effects; D010088:Oxidoreductases / Q000187:drug effects; D010940:Plant Proteins; D000099188:Alternative Oxidase
D000981:Antiprotozoal Agents; D002482:Cellulose; D003598:Cytoskeletal Proteins; D024101:Mitochondrial Proteins; D009955:Ornithine Decarboxylase; D010088:Oxidoreductases; D010940:Plant Proteins; D000099188:Alternative Oxidase